Repare Therapeutics Inc. (RPTX)
0.92
0.02 (2.22%)
At close: Apr 14, 2025, 3:59 PM
2.22% (1D)
| Bid | 0.9 |
| Market Cap | 39.02M |
| Revenue (ttm) | 53.48M |
| Net Income (ttm) | -84.69M |
| EPS (ttm) | -2 |
| PE Ratio (ttm) | -0.46 |
| Forward PE | -0.46 |
| Analyst | Buy |
| Ask | 0.97 |
| Volume | 687,054 |
| Avg. Volume (20D) | 234,459 |
| Open | 0.92 |
| Previous Close | 0.90 |
| Day's Range | 0.90 - 0.93 |
| 52-Week Range | 0.89 - 4.29 |
| Beta | 0.91 |
About RPTX
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an ora...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 19, 2020
Employees 129
Stock Exchange NASDAQ
Ticker Symbol RPTX
Website https://www.reparerx.com
Analyst Forecast
According to 3 analyst ratings, the average rating for RPTX stock is "Buy." The 12-month stock price forecast is $4.5, which is an increase of 390.20% from the latest price.
Stock ForecastsNext Earnings Release
Repare Therapeutics Inc. is scheduled to release its earnings on May 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
-55.42%
Repare Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
6 months ago
+0%
Repare Therapeutics shares are trading higher after the company announced it will present its Phase 1 data highlighting Camonsertib in combination with radiotherapy treatment at the ASTRO annual meeting
